Oncology

trop2-inhibitors-for-cancer-treatment

Others

SITC 2024 Summary: Quick Recap of what all happened during this year’s annual meeting

Explore More...
medtech-news-for-roche-bausch-lomb-abbott

Roche Receives FDA Approval for Itovebi; FDA Approves Bausch + Lomb’s Envista® Envy™; Microbot Medical Successfully Completes Pivotal Human Clinical Trial and Accelerates Go-to-Market Strategy for LIBERTY® Launch; Positive FDA Guidance on Phase III Trial of 64Cu-SAR-Bispsma for Recurrent Prostate Cancer; ELEHEAR Launches Hearing Aids at Just $399; Abbott Advances Pulsed Field Ablation Studies and Launches New Technology for Cardiac Mapping

Pharma-news-for-astellas-gsk-astrazeneca

Astellas & AviadoBio’s Exclusive Deal for AVB-101; GSK’s Depemokimab Shows Positive Results for Nasal Polyps; Lilly’s Mirikizumab Outperforms Ustekinumab in Crohn’s Study; TREMFYA Delivers Strong Results in Crohn’s & Colitis; ENHERTU Approved in China for HER2-Mutant NSCLC.

late-stage-prostate-cancer-drugs

12 Breakthrough Prostate Cancer Drugs in Late-Stage Development 

glioma-vs-glioblastoma-therapeutics-space

Glioma vs. Glioblastoma Therapeutics Space: Unveiling the Battlefront

Most asked questions about Glioblastoma multiforme

13 of the most commonly asked questions about Glioblastoma multiforme, Answered

GBM-Market-Glioblastoma-Multiforme-Therapeutic-Advancements

Glioblastoma Multiforme: Advancements in the Treatment Paradigm of the Malignant Condition

Glioblastoma Multiforme Market Emerging Pipeline Therapies To Keep A Keen Eye On

Glioblastoma Multiforme Market: Emerging Pipeline Therapies To Keep A Keen Eye On

Glioblastoma multiforme Treatment Market GBM Treatment Market

Huge Unmet Needs in the Glioblastoma Multiforme Treatment Market Driving the Market Size Growth

pharma-news-for-bms-palvella-orogen

OPDIVO Approved for Resectable NSCLC; Palvella Gets $2.6M FDA Grant; First Patient Dosed in UGN-103 Bladder Cancer Trial; Recordati Acquires ENJAYMO for $825 Million; AIRSUPRA Reduces Severe Asthma Exacerbations

7-key-companies-developing-trispecific-antibodies

7 Companies at the Forefront of Trispecific Antibody Development

medtech-news-for-establishment-labs-surmodics-medtronic

Establishment Labs Gains FDA Approval for Motiva Implants; Surmodics Receives 510(k) Clearance for Pounce™ XL Thrombectomy System; Synergy Spine Solutions Completes Patient Enrollment in Synergy Disc® 2-Level IDE Clinical Trial; Medtronic Reports Strong Lesion Durability Data for PulseSelect™ Ablation System and Expands AiBLE™ Spine Surgery Ecosystem with Siemens Healthineers Partnership; Globus Medical Launches New Orthopedic Trauma Solutions

gastrointestinal-cancers-and-their-types

Gastrointestinal Cancers: Exploring the Range of Digestive Tract Malignancies

Pharma-news-for-bms-intrabio-pfizer

IntraBio’s AQNEURSA Niemann-Pick Disease Approval; FDA Approves Novel Schizophrenia Drug After 35 Years; Selpercatinib Gets FDA Nod for RET-Mutated MTC; DUPIXENT Receives First-Ever COPD Approval; Pfizer Withdraws OXBRYTA for Sickle Cell Disease from Global Market

prostate-cancer-awareness-month

Prostate Cancer Awareness Month: Early Detection Saves Lives!!

Pharma-news-for-astrazeneca-sanofi-UCB

Zevra’s MIPLYFFA Niemann-Pick Disease Approval; FASENRA Approved for Eosinophilic Granulomatosis; Sanofi’s SARCLISA Gets Multiple Myeloma Approval; RYBREVANT Combo Gets FDA Nod for EGFR Lung Cancer; UCB’s BIMZELX Receives Multiple Approval from the FDA

cd38-directed-therapies-for-multiple-myeloma-treatment

Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader